Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$16.85 USD
+0.69 (4.27%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.84 -0.01 (-0.06%) 4:42 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Cartesian Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -219.71 | 35.38 | -25.69 | -68.88 | -55.35 |
Depreciation/Amortization & Depletion | 0.76 | 0.91 | 1.31 | 0.73 | 1.87 |
Net Change from Assets/Liabilities | 4.97 | -60.38 | -48.19 | 85.00 | -4.48 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 162.81 | -7.55 | 12.19 | 18.02 | 6.52 |
Net Cash From Operating Activities | -51.16 | -31.63 | -60.38 | 34.88 | -51.44 |
Property & Equipment | -0.21 | -1.20 | -1.09 | -0.74 | 0.08 |
Acquisition/ Disposition of Subsidiaries | 6.56 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 28.25 | -13.80 | -16.06 | 0.00 | 0.15 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 34.61 | -15.00 | -17.14 | -0.74 | 0.23 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 20.48 | 39.33 | 52.90 | 13.73 | 102.13 |
Issuance (Repayment) of Debt | -27.46 | 0.00 | 0.00 | 5.42 | -2.80 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -6.17 | -0.11 | 0.00 | -4.72 | 5.72 |
Net Cash from Financing Activities | -13.15 | 39.22 | 52.90 | 14.43 | 105.04 |
Effect of Exchange Rate Changes | -0.05 | 0.02 | 0.00 | -0.06 | 0.03 |
Net Change In Cash & Equivalents | -29.75 | -7.40 | -24.63 | 48.51 | 53.87 |
Cash at Beginning of Period | 108.04 | 115.44 | 140.06 | 91.55 | 37.68 |
Cash at End of Period | 78.29 | 108.04 | 115.44 | 140.06 | 91.55 |
Diluted Net EPS | -49.85 | 3.00 | -6.61 | -20.42 | -36.64 |
Fiscal Year End for Cartesian Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -56.82 | -219.71 | -42.05 | -33.05 |
Depreciation/Amortization & Depletion | NA | 0.18 | 0.76 | 0.49 | 0.30 |
Net Change from Assets/Liabilities | NA | -6.37 | 4.97 | 8.88 | 8.92 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 47.09 | 162.81 | 4.80 | 5.17 |
Net Cash From Operating Activities | NA | -15.92 | -51.16 | -27.88 | -18.66 |
Property & Equipment | NA | -0.60 | -0.21 | -0.14 | -0.14 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 6.56 | 0.00 | 0.00 |
Investments | NA | 0.00 | 28.25 | 28.25 | 28.25 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.60 | 34.61 | 28.11 | 28.11 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 43.03 | 20.48 | 0.23 | 0.15 |
Issuance (Repayment) of Debt | NA | 0.00 | -27.46 | -27.46 | -2.59 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | -6.17 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 43.03 | -13.15 | -27.23 | -2.44 |
Effect of Exchange Rate Changes | NA | -0.01 | -0.05 | -0.07 | -0.05 |
Net Change In Cash & Equivalents | NA | 26.51 | -29.75 | -27.06 | 6.97 |
Cash at Beginning of Period | NA | 78.29 | 108.04 | 108.04 | 108.04 |
Cash at End of Period | NA | 104.80 | 78.29 | 80.98 | 115.00 |
Diluted Net EPS | NA | -10.50 | -41.74 | -1.80 | -2.10 |